Navigation Links
Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineered therapy selectively embeds a gene in pancreatic cancer that shrinks or eradicates tumors, inhibits metastasis, and prolongs survival with virtually no toxicity, researchers from The University of Texas M. D. Anderson Cancer Center report in the July 9 edition of Cancer Cell.

"This vehicle, or vector, is so targeted and robust in its cancer-specific expression that it can be used for therapy and perhaps for imaging," notes senior author Mien-Chie Hung, Ph.D., professor and chair of M. D. Anderson's Department of Molecular and Cellular Oncology.

The researchers call the system a versatile expression vector - nicknamed VISA. It includes a targeting agent, also called a promoter, two components that boost gene expression in the target tissue, and a payload - in this case a gene known to kill cancer cells. It's all packaged in a fatty ball called a liposome and delivered intravenously.

Researchers are working with M. D. Anderson clinicians to move the system, developed and tested in mouse models of pancreatic cancer, to a Phase I clinical trial.

"This looks like a promising approach to gene therapy for pancreatic cancer and we are working to bring it to a clinical trial," says James Abbruzzese, M.D., professor and chair of the M. D. Anderson Department of Gastrointestinal Oncology.

He estimates that it will take between one and two years to complete U.S. Food and Drug Administration requirements for a Phase I trial. Abbruzzese's clinicians are working with Hung's group to compile preclinical information for FDA review.

About 37,000 cases of pancreatic cancer are diagnosed annually in the United States. Early diagnosis is extremely difficult, so the disease is often discovered at a late stage after it already has spread, or metastasized. Fewer than 4 percent of pancreatic cancer patients survive five years after diagnosis, one
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
5. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
6. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
7. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 ... has been commenced in the United States District Court ... on behalf of investors who purchased Galectin Therapeutics Inc. ... 6, 2014 and July 28, 2014. For ... The complaint alleges that during the Class Period the ...
(Date:8/28/2014)...   Edison Nation Medical , the premier ... for product ideas to improve the health and ... through the 6-month search ( www.EdisonNationMedical.com/Seniors ) will ... healthcare retailers with whom Edison Nation Medical has ... 65 and older. The objective of ...
(Date:8/28/2014)...  Seres Health, a clinical-stage therapeutics company developing ... microbiome, announced today that Dr. David Cook ... Chief Scientific Officer, will be presenting at the ... (ICAAC). The presentation will highlight the scientific and ... bacterial spores derived from the human microbiome, and ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2
... CRAIGAVON, Northern Ireland , August 2, 2010 ... a range of solutions,specifically designed to meet the needs of the ... , ... biopharma companies in adopting,biomarker strategies to enable them to better understand ...
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that ... Healthcare Conference on Thursday, August 5, 2010 at 1:15 ... held at the Sheraton New York Hotel & Towers.  Steve Worland, Ph.D., ... Anadys and its clinical development programs. , ...
Cached Medicine Technology:Almac Launch Biomarkers for Biopharma 2Almac Launch Biomarkers for Biopharma 3Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference 2
(Date:8/28/2014)... 28, 2014 The Governor of Yucatán, ... at a press conference; this event is organized ... Ministry of Economy through the National Microenterprise Financing Program ... 2nd to the 5th at the Convention Center Yucatan ... is a great responsibility for Yucatan to host the ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for ... new world’s record by walking 5,000 miles in a single ... amazed by the thousands of individual stories of TrekDesk treadmill ... stand out more than the others. , Kirklyn has launched ... which tallies a range of 54,823 steps (presumably on an ...
(Date:8/28/2014)... Bank lending to the private sector in the ... in real terms, and continuing to fall behind the rest ... the international accountancy network. , UHY warns that the figures ... credit crunch lingers on. , UHY says in the US, ... been wiped out by inflation. Over the four years since ...
(Date:8/28/2014)... sleep not only puts teens at risk for poor grades, ... warn. The study authors analyzed data collected from more ... Nearly one-fifth of them got less than six hours of ... group was 20 percent more likely to be obese at ... of sleep per night at age 16, the investigators found. ...
(Date:8/28/2014)... the earliest birds take wing? Did they fall from trees ... did they run along the ground and pump their "arms" ... years in the past, but a new University of California, ... have an innate ability to maneuver in midair, a talent ... than fall from a perch. , The study looked at ...
Breaking Medicine News(10 mins):Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3
... Annual JMP Securities Research Conference ... on May 21 - ... Meeting on May 22 -, SAN DIEGO, May 14 Ardea Biosciences, Inc.,(Nasdaq: ... Annual Research Conference. Additionally, Ardea will be,hosting a live webcast and conference call of ...
... 14 Biotel Inc. (OTC Bulletin,Board: BTEL) announced results ... earnings of $99,000, or $0.03 per diluted share, on ... or $0.07 per diluted,share, on revenues of $2,990,000 for ... ended March 31, 2008, Biotel had net earnings of ...
... Patients more likely to survive using chemoradiation, and new ... -- Tonsil and tongue cancers linked to human papillomavirus ... treatments, while those that express high levels of a ... most deadly, a new study concludes. , University of ...
... other treatments work well, too, giving patients options , , WEDNESDAY, ... kind supports the use of a popular three-drug regimen for ... drugs is a good alternative. , But an older ... Sharon Riddler, assistant professor of medicine at the University of ...
... , , WEDNESDAY, May 14 (HealthDay News) -- A bundle of ... cardiovascular disease in a study of older Swedish men, researchers ... long process that might one day lead to widespread medical ... such as high blood pressure and cholesterol, said Dr. Johan ...
... Honored for Their Research -, PALO ALTO, ... Ph.D. students and two professors with the company,s ... field of organic,chemistry. The winners participated in Roche,s ... on the important role of organic,chemistry in pharmaceutical ...
Cached Medicine News:Health News:Ardea Biosciences Announces Upcoming Corporate Meetings 2Health News:Ardea Biosciences Announces Upcoming Corporate Meetings 3Health News:Biotel Announces Profitable Third Quarter Ended March 31, 2008 2Health News:HPV Tied to Better Tongue, Tonsil Cancer Outcomes 2Health News:Study Supports Popular HIV Drug Regimen 2Health News:Study Supports Popular HIV Drug Regimen 3Health News:Biomarkers Predict Heart Deaths 2Health News:Biomarkers Predict Heart Deaths 3Health News:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 2Health News:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 3
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Medicine Products: